Improving Treatments - Improving Lives

Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development of LCP-Tacro for the prevention of organ rejection in kidney transplant patients.

FEATURED INFORMATION

May 16, 2013
Presentation of Interim Report for the 1st Quarter 2013

	Q1 2013 Interim Report 680.3 KB
	Q1 2013 Interim Report (DK) 700.4 KB
	Q1 2013 Presentation 321.0 KB
	Audiocast

Veloxis' Management will host a conference call to discuss the financial results on Thursday 16 May, 2013 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EST (New York),

To access the live conference call, please dial one of the following numbers:

+45 32 72 80 18 (Denmark)

+44 (0) 1452 555 131 (UK)

+1 866 682 8490 (USA)

Access code 64307755